A Systematic Review on Levosimendan in Paediatric Patients | Bentham Science
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

A Systematic Review on Levosimendan in Paediatric Patients

Author(s): Simona Silvetti, Paolo Silvani, Maria Luisa Azzolini, Roberto Dossi, Giovanni Landoni and Alberto Zangrillo

Volume 13, Issue 1, 2015

Page: [128 - 133] Pages: 6

DOI: 10.2174/1570161112666141127163536

Price: $65

Open Access Journals Promotions 2
Abstract

Levosimendan is a calcium-sensitizing agent that improves cardiac function, hemodynamic performance, and survival in critically ill adult patient. Few data exist on its off-label use in paediatric patients. We therefore performed a systematic review updated in September 2013 of all the published articles describing the use of levosimendan in paediatric patients. We identified 24 studies published in the period 2004-2013 that included a total of 623 patients, the largest one being a case series of 293 patients. Most of the patients underwent cardiac surgery, other settings consisting of chronic heart failure, primary congenital heart diseases and sepsis and cancer-associated cardiac dysfunction. Most studies reported improvement in ventricular function, central venous oxygen saturation, serum lactate levels or cardiac index. The 5 randomized studies published so far have all been performed in cardiac surgery and suggest a beneficial effect on hemodynamic data with no effect on intensive care unit stay, hospital stay or survival. Side effects (e.g. hypotension) were reported. This inodilator merits to be investigated with further randomized trials focusing on clinically relevant outcomes.

Keywords: Cardiac surgery, chronic heart failure, congenital heart diseases, hemodynamic effect, levosimendan, paediatric patients, systematic review.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy